skip to main content
OSTI.GOV title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: Biodistribution of indium-111-labeled OC 125 monoclonal antibody intraperitoneally injected into patients operated on for ovarian carcinomas

Abstract

The biodistribution of 111In-labeled monoclonal antibody (MAb) OC 125 was studied after i.p. injection in 28 patients who underwent surgery for ovarian carcinoma. Group I (eight patients) received intact 111In-labeled OC 125 MAb, Group II (three patients) intact 111In-labeled irrelevant NS, Group III (five patients) intact 111In-labeled OC 125 MAb associated with 20 mg of the same unlabeled MAb and Group IV (12 patients) F(ab')2 fragments of 111In-labeled OC 125 MAb. The patients were operated on 1 to 3 days after i.p. injection, and the surgeon removed large tumor fragments and/or small tumor nodules and, in some patients, collected the residual perfusion fluid from which malignant cell clusters were isolated. Uptake by large tumor fragments at 24 h was low: 0.0031 +/- 0.0032% injected dose per gram (%ID/g) for Group I and 0.0024 +/- 0.0022%ID/g for Group IV. It was moderately higher than that of Group II (0.0014 +/- 0.0006%ID/g) and Group III (0.0015 +/- 0.0007%ID/g). Uptake by small tumor nodules (0.1302 +/- 0.0802%ID/g at 72 h for Group I) and malignant cell clusters (median: 0.3322, with a maximum value of 4.1614%ID/g at 24 h for Group IV) was markedly higher. Tumor-to-normal tissue ratios with OC 125 MAb (intact ormore » F(ab')2 fragments) ranged between 0.1 and 8.5 for large tumor fragments and 2 and 8,700 for small tumor nodules and malignant cell clusters. It would thus appear that RIT is feasible if an appropriate radionuclide can be selected for antibody labeling.« less

Authors:
; ; ; ; ; ; ; ; ;  [1]
  1. Faculte de Medecine, Nantes (France)
Publication Date:
OSTI Identifier:
5402096
Resource Type:
Journal Article
Journal Name:
Cancer Research; (USA)
Additional Journal Information:
Journal Volume: 49:11; Journal ID: ISSN 0008-5472
Country of Publication:
United States
Language:
English
Subject:
62 RADIOLOGY AND NUCLEAR MEDICINE; CARCINOMAS; RADIOIMMUNOTHERAPY; MONOCLONAL ANTIBODIES; TISSUE DISTRIBUTION; OVARIES; ANTIGENS; IMMUNOGLOBULINS; INDIUM 111; INTRAPERITONEAL INJECTION; PATIENTS; ANTIBODIES; BETA DECAY RADIOISOTOPES; BODY; DAYS LIVING RADIOISOTOPES; DISEASES; DISTRIBUTION; ELECTRON CAPTURE RADIOISOTOPES; FEMALE GENITALS; GLOBULINS; GONADS; IMMUNOLOGY; IMMUNOTHERAPY; INDIUM ISOTOPES; INJECTION; INTAKE; INTERMEDIATE MASS NUCLEI; ISOMERIC TRANSITION ISOTOPES; ISOTOPES; MEDICINE; MINUTES LIVING RADIOISOTOPES; NEOPLASMS; NUCLEAR MEDICINE; NUCLEI; ODD-EVEN NUCLEI; ORGANIC COMPOUNDS; ORGANS; PROTEINS; RADIOIMMUNOLOGY; RADIOISOTOPES; RADIOLOGY; RADIOTHERAPY; THERAPY; 550604* - Medicine- Unsealed Radionuclides in Therapy- (1980-)

Citation Formats

Chatal, J F, Saccavini, J C, Gestin, J F, Thedrez, P, Curtet, C, Kremer, M, Guerreau, D, Nolibe, D, Fumoleau, P, and Guillard, Y. Biodistribution of indium-111-labeled OC 125 monoclonal antibody intraperitoneally injected into patients operated on for ovarian carcinomas. United States: N. p., 1989. Web.
Chatal, J F, Saccavini, J C, Gestin, J F, Thedrez, P, Curtet, C, Kremer, M, Guerreau, D, Nolibe, D, Fumoleau, P, & Guillard, Y. Biodistribution of indium-111-labeled OC 125 monoclonal antibody intraperitoneally injected into patients operated on for ovarian carcinomas. United States.
Chatal, J F, Saccavini, J C, Gestin, J F, Thedrez, P, Curtet, C, Kremer, M, Guerreau, D, Nolibe, D, Fumoleau, P, and Guillard, Y. 1989. "Biodistribution of indium-111-labeled OC 125 monoclonal antibody intraperitoneally injected into patients operated on for ovarian carcinomas". United States.
@article{osti_5402096,
title = {Biodistribution of indium-111-labeled OC 125 monoclonal antibody intraperitoneally injected into patients operated on for ovarian carcinomas},
author = {Chatal, J F and Saccavini, J C and Gestin, J F and Thedrez, P and Curtet, C and Kremer, M and Guerreau, D and Nolibe, D and Fumoleau, P and Guillard, Y},
abstractNote = {The biodistribution of 111In-labeled monoclonal antibody (MAb) OC 125 was studied after i.p. injection in 28 patients who underwent surgery for ovarian carcinoma. Group I (eight patients) received intact 111In-labeled OC 125 MAb, Group II (three patients) intact 111In-labeled irrelevant NS, Group III (five patients) intact 111In-labeled OC 125 MAb associated with 20 mg of the same unlabeled MAb and Group IV (12 patients) F(ab')2 fragments of 111In-labeled OC 125 MAb. The patients were operated on 1 to 3 days after i.p. injection, and the surgeon removed large tumor fragments and/or small tumor nodules and, in some patients, collected the residual perfusion fluid from which malignant cell clusters were isolated. Uptake by large tumor fragments at 24 h was low: 0.0031 +/- 0.0032% injected dose per gram (%ID/g) for Group I and 0.0024 +/- 0.0022%ID/g for Group IV. It was moderately higher than that of Group II (0.0014 +/- 0.0006%ID/g) and Group III (0.0015 +/- 0.0007%ID/g). Uptake by small tumor nodules (0.1302 +/- 0.0802%ID/g at 72 h for Group I) and malignant cell clusters (median: 0.3322, with a maximum value of 4.1614%ID/g at 24 h for Group IV) was markedly higher. Tumor-to-normal tissue ratios with OC 125 MAb (intact or F(ab')2 fragments) ranged between 0.1 and 8.5 for large tumor fragments and 2 and 8,700 for small tumor nodules and malignant cell clusters. It would thus appear that RIT is feasible if an appropriate radionuclide can be selected for antibody labeling.},
doi = {},
url = {https://www.osti.gov/biblio/5402096}, journal = {Cancer Research; (USA)},
issn = {0008-5472},
number = ,
volume = 49:11,
place = {United States},
year = {Thu Jun 01 00:00:00 EDT 1989},
month = {Thu Jun 01 00:00:00 EDT 1989}
}